Prostate-Specific Antigen Progression Predicts Overall Survival in Patients With Metastatic Prostate Cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
Year: 2009
Type: article
Abstract: PURPOSE: Prostate-specific antigen progression (PSA-P) is an indicator of progression in hormone-sensitive (HS) and castration-resistant (CR) prostate cancer (PC). We evaluated different definitions of PSA-P as predictors of overall survival (OS). PATIENTS AND METHODS: A total of 1,078 patients with HSPC who were on hormones (Southwest Oncology Group [SWOG] trial 9346 [S9346]) and 597 patients with CRPC who were treated with chemotherapy (SWOG trial 9916 [S9916]) were eligible for this analysis. PSA-P definitions tested included the following: PSA Working Group, Prostate Cancer Working Group (PCWG 2008), and other definitions. A time-varying approach analyzed associations between PSA-P at any time and OS. A landmark analysis examined the relationship between PSA-P status at 7 months for S9346, or 3 months for S9916, and subsequent OS. RESULTS: In the time-varying analysis, both working groups definitions were strongly associated with OS (P < .001) in both study settings. In patients enrolled onto S9346, both definitions predicted a 2.4-fold increased risk of death (ROD) and a greater than four-fold increased ROD if PSA-P occurred in the first 7 months. In S9916, they predicted a 40% increase in ROD and a two-fold increase in ROD if PSA-P occurred at 3 months. In landmark analyses of patients on S9346 by using the PCWG 2008 definition of PSA-P, median subsequent OS was 10 months versus 44 months in patients who did or did not have PSA-P by 7 months, respectively; in S9916, data were 11 months versus 18 months for patients who did or did not have PSA-P by 3 months, respectively. CONCLUSION: PSA-P, defined as an increase of > or = 25% greater than the nadir and an absolute increase of at least 2 or 5 ng/mL, predicts OS in HSPC and CRPC and may be a suitable end point for phase II studies in these settings.
Source: Journal of Clinical Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: SOUTHWEST ONCOLOGY GROUP, G1033243903, G1063828809, G117886320, G1202672505, G1216887118, G1235982543, SOUTHWEST ONCOLOGY GROUP, G1257575315, G1312097577, G1318263859, G1331445602, G1343089328, G1375689152, Columbus Community Clinical Oncology Program (Columbus CCOP), G1469275664, G1545560008, G1549000524, G1570777714, G1646027999, COOPERATIVE STUDY OF CANCER CHEMOTHERAPY, G1790576020, G1794831901, G1911575068, G1958973285, G1985252453, G2043432835, G2057923966, G2064543036, Scott & White Community Clinical Oncology Program, G2201816905, G2237949143, G2276667821, G2296793909, G2320693132, G2345882982, G2419449687, G2435896781, G2485941414, G2562936776, G2679961467, G268786457, G2734683319, G2750730928, COLUMBIA UNIVERSITY SOUTHWEST ONCOLOGY GROUP PROGRAM, G2789970137, Ozark Health Ventures, LLC dba Cancer Research for the Ozarks, GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM, G3041257426, SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER, G3126600779, G313314762, G3242537740, Southeast Cancer Control Consortium, Inc, G3295642875, G3334379738, G3337849518, G345775953, G3484997517, G3497039781, G3521018462, G358241105, City of Hope Southwest Oncology Group Clinical Trials, G36541222, G3710026009, G3737421695, G379387698, G3939550896, G398851121, G4110529384, G413878341, SOUTHWEST ONCOLOGY GROUP--CLINICAL TRIALS, G425646771, G4271794948, Southwest Oncology Group, G4292856267, G444114835, Southwest Oncology Group, G4499432180, G4527800867, SOUTHWEST ONCOLOGY GROUP, G4719029039, G4935167430, G5187432406, G5264753430, CANCER AND LEUKEMIA GROUP B, G5519497345, G5566132837, G591690631, SOUTHWEST ONCOLOGY GROUP, North Central Cancer Treatment Group, SOUTHWEST ONCOLOGY GROUP, G6286696974, G6723594983, SOUTHWEST ONCOLOGY GROUP, G6782300252, SOUTHWEST ONCOLOGY GROUP STUDIES, G6895959609, G6943608702, G7061256793, G721629745, G7222907299, G7230571265, CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM, SOUTHWEST ONCOLOGY GROUP STUDY, G7520596819, G758084519, Virginia Mason Community Clinical Oncology Program, G763325562, G7860541851, EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES, G7926913928, G8006406963, G8036334546, G8116866424, G8156375866, Eastern Cooperative Oncology Group Operations Office, G8413228103, G8523218764, PRECLINICAL PROSTATE CANCER CHEMOPREVENTION STUDIES, G860872252, G869916006, SOUTHWEST ONCOLOGY GROUP, G8740717309, G886666726, PARTICIPATE AS MEMBER OF SOUTHWEST ONCOLOGY GROUP, G924713883, G933283670, G937543590, G942110296, G964706321, G971274320
OpenAlex ID: W2026102934